Watch Corporate Video

Hetero Biopharma organised Paramedical Staff Debut education programme @ Uganda

Hetero Biopharma, a biologics arm of Hetero has organized first of its kind, customized workshop on the challenges faced by dialysis nurses in their day to day practice on 18th October at Piato Restaurant Kampala

Nursing or the dialysis staff face multiple compliance bottlenecks in terms of dosage titration, administration, storage, maintenance of records of dialysis, handling needle stick injuries, identification of counterfeit medicine and so forth and so on.

Workshop was aimed to educate the nursing staff on basics of anaemia, role of DERISE(Darbepoetin alfa) in treating anaemia, ease of dose titration with Darbepoetin was well presented by Dr Kigundu Dan, Nephrologist @ Nakasiro hospital Uganda. Innovative anti-counterfeiting packaging with security feature developed by Hetero Biopharma was presented by our colleague Mr.Emma Gizambe. Importance of accurate titration in dose and time savings, way to administer pre filled syringes to avoid needle stick injuries was well demonstrated.

More than 25 nurses and para medical staff from various dialysis centres and hospitals of Kampala has actively participated in the workshop. The event created a platform for the nursing staff to discuss, on the go issues they face during the dialysis process.

Indeed it was the great efforts by the HBL Africa team headed by Mr.Krishna Kishore Regional Head- Africa Biosimilars Business and team, marketing support led by Dr.A V Jayapala Reddy AVP & Global Head- Biologics Business, Mr. Ramesh Reddy Manager – Marketing, Sharath Devalapelly – Asst Manager- Marketing, created a positive scope for biosimilars in Nephrology space in Africa.

Under KBB (Knowledge Beyond Borders), a global knowledge exchange initiative of Hetero Biopharma we firmly believe that engaging the medical staff in conferences and workshops, helps us in raising awareness on biosimilars and unique products like Derise(Darbepoetin) to the medical fraternities in emerging markets.